Durenard Eugene 4

What Happened

• Eugene Durenard, a director of Co-Diagnostics, acquired 1,695 shares on May 23, 2026 through the conversion/settlement of restricted stock units (reported as a grant/acquisition at $0). The filing also shows a corresponding derivative transaction (code M) for 1,695 units at $0, reflecting conversion/exercise of the derivative into common shares. The Form 4 reports $0 as the reported purchase price because these shares were issued as compensation (not an open-market cash purchase).

Key Details

• Transaction date: May 23, 2026
• Transactions reported: A (award/acquisition) 1,695 shares @ $0.00; M (exercise/conversion of derivative) 1,695 shares @ $0.00
• Consideration: $0 reported (shares issued/converted as compensation/RSU settlement)
• Shares owned after transaction: Not specified in the filing
• Footnote: These shares are included in previously awarded restricted stock units from June 12, 2023; April 26, 2024; and August 13, 2025, which vest in scheduled installments (see filing for full vesting schedule)
• Timeliness: Report filed May 27, 2026 for a May 23, 2026 transaction—appears timely (not marked late)

Context

• Code M indicates conversion/exercise of a derivative (here, RSUs) into common stock; code A reflects the acquisition of the issued shares. Because this was a compensation-related issuance (RSU vesting/settlement) reported at $0, it differs from an open-market purchase or sale and does not by itself indicate buying or selling sentiment.